DigiNXT Solution

TRACON Pharmaceuticals Inc TCON Stock Price Today, News, Quotes, FAQs and Fundamentals


Transparency is how we protect the integrity of our work and keep empowering investors to achieve their goals and dreams. And we have unwavering standards for how we keep that integrity intact, from our research and data to our policies on content and your personal data. Take your analysis to the next level with our full suite of features, known and used by millions throughout the trading world. On the date of publication, William White did not have any positions in the securities mentioned in this article. The opinions expressed in this article are those of the writer, subject to the InvestorPlace.com Publishing Guidelines.

Tracon Pharmaceuticals Plunges after Unfavorable Arbitration Ruling – TipRanks

Tracon Pharmaceuticals Plunges after Unfavorable Arbitration Ruling.

Posted: Tue, 25 Apr 2023 15:52:21 GMT [source]

Upgrade to the female spies of the soeBeat All Access to add more stocks to your watchlist. Only 5.27% of the stock of TRACON Pharmaceuticals is held by insiders. 2 people have added TRACON Pharmaceuticals to their MarketBeat watchlist in the last 30 days.

Market cap, also known as market capitalization, is the total market value of a company. It’s calculated by multiplying the current market price by the total number of shares outstanding. Moody’s Daily Credit Risk Score is a 1-10 score of a company’s credit risk, based on an analysis of the firm’s balance sheet and inputs from the stock market. The score provides a forward-looking, one-year measure of credit risk, allowing investors to make better decisions and streamline their work ow. Updated daily, it takes into account day-to-day movements in market value compared to a company’s liability structure. Today’s legal news has shares of TCON stock seeing heavy trading on Tuesday.

TRACON Pharmaceuticals Analyst Opinions

This suggests a possible upside of 1,150.3% from the stock’s current price. View analysts price targets for TCON or view top-rated stocks among Wall Street analysts. We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions.

Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations.

TRACON Pharmaceuticals Insider Activity

52 week high is the highest price of a stock in the past 52 weeks, or one year. TRACON Pharmaceuticals Inc 52 week high is $2.37 as of April 28, 2023. © 2023 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided ‘as-is’ and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart’s disclaimer. One share of TCON stock can currently be purchased for approximately $0.80.

market capitalization

They rarely distribute https://1investing.in/s to shareholders, opting for reinvestment in their businesses. More value-oriented stocks tend to represent financial services, utilities, and energy stocks. A look at the daily price movement shows that the last close reads $1.78, with intraday deals fluctuated between $0.805 and $1.20.

Related News TCON

I-Mab intends to accelerate development and global partnership for uliledlimab and bi-specific antibody assets, which have the potential to create value for it as soon as early 2024. 1) a collaboration agreement to co-develop I-Mab’s proprietary CD73 antibody uliledlimab ; and 2) a collaboration agreement to potentially co-develop I-Mab’s bi-specific antibodies . Provide specific products and services to you, such as portfolio management or data aggregation.

According to analysts’ consensus price target of $10.00, TRACON Pharmaceuticals has a forecasted upside of 1,119.5% from its current price of $0.82. These three biotech companies have all had insiders buying shares recently. You can find your newly purchased TCON stock in your portfolio—alongside the rest of your stocks, ETFs, crypto, and alternative assets. The arbitration award denied Tracon’s damages claim of over $200M for any breach under the BsAb agreement and awarded no damages to Tracon, I-Mab added. The technique has proven to be very useful for finding positive surprises. In fact, when combining a Zacks Rank #3 or better and a positive Earnings ESP, stocks produced a positive surprise 70% of the time, while they also saw 28.3% annual returns on average, according to our 10 year backtest.

Market capitalization is calculated by taking a company’s share price and multiplying it by the total number of shares. In the Morningstar Style Box, large-cap names account for the largest 70% of U.S. stocks, mid-cap names account for the largest 70–90%, and small-cap names are the remaining 10% of companies. The 50-day moving average is a frequently used data point by active investors and traders to understand the trend of a stock. It’s calculated by averaging the closing stock price over the previous 50 trading days.

TRACON Pharmaceuticals Shareholder

That shoots down its attempt at claiming $200 million in damages from I-Mab. However, I-Mab will have to pay $13.5 million in TCON’s legal fees. The bad news for TCON stock comes from a legal ruling favoring I-Mab. That ruling determines that I-Mab doesn’t have to pay any damages to TRACON Pharmaceuticals. TRACON Pharmaceuticals’ stock is owned by a number of retail and institutional investors. Top institutional shareholders include Simplex Trading LLC (0.00%).

Shares of Tracon Pharmaceuticals Inc. were up 29% in premarket trading on Friday after the company said it would partner with two Chinese companies to develop its investigational soft tissue sarcoma therapy in North Ameri… Staying with the analyst view, there is a consensus estimate of $3 million for the company’s annual revenue in 2023. Raised $47 million in an initial public offering on Friday, January 30th 2015. The company issued 3,600,000 shares at $12.00-$14.00 per share. Wells Fargo Securities and Stifel acted as the underwriters for the IPO and Needham & Company and Oppenheimer were co-managers. 0.55% of the outstanding shares of TRACON Pharmaceuticals have been sold short.

MarketInsightsReports provides global and regional market intelligence coverage, a 360-degree market view which includes statistical forecasts, competitive landscape, detailed segmentation, key trends, and strategic recommendations. However, based on the arbitration award, I-Mab will bear a portion of Tracon’s legal fees and costs of about $13.5M. Morningstar Quantitative ratings for equities are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. TRACON Pharmaceuticals and I-Mab signed a collaboration agreement for the development of CD73 antibody uliledlimab.

As of this writing, more than 635,000 shares of the stock have changed hands. For comparison, the company’s daily average trading volume is about 75,000 shares. Keep in mind that other fees such as regulatory fees, Premium subscription fees, commissions on trades during extended trading hours, wire transfer fees, and paper statement fees may apply to your brokerage account. Please see Open to the Public Investing’s Fee Schedule to learn more.

No offer to buy securities can be accepted, and no part of the purchase price can be received, until an offering statement filed with the SEC has been qualified by the SEC. An indication of interest to purchase securities involves no obligation or commitment of any kind. The report also sheds light on the evaluation of growth opportunities, challenges, market threats and constraining factors of the TCON Chip Market. It studies local regional as well as global market and emerging segments, and market dynamics also.

dow jones

Market Cap is calculated by multiplying the number of shares outstanding by the stock’s price. To calculate, start with total shares outstanding and subtract the number of restricted shares. Restricted stock typically is that issued to company insiders with limits on when it may be traded.Dividend YieldA company’s dividend expressed as a percentage of its current stock price. Current records show that the company has 22.31M in outstanding shares. The insiders’ percentage holdings are 1.50% of outstanding shares while the percentage share held by institutions stands at 45.90%.

Companies to develop and commercialize innovative products in the United States. The company’s drug candidate includes Envafolimab, TRC102, TRC253, and Bispecific Antibodies. Revisions to the company’s EPS highlights a short term direction of a stock’s price movement, which in the last 7 days came up with no upward and no downward reviews. On the technical perspective front, indicators give TCON a short term outlook of 50% Buy on average.

TRACON Pharmaceuticals Announces Arbitration Award in Dispute with I-Mab

Zacks Earnings ESP looks to find companies that have recently seen positive earnings estimate revision activity. The idea is that more recent information is, generally speaking, more accurate and can be a better predictor of the future, which can give investors an advantage in earnings season. Maintaining independence and editorial freedom is essential to our mission of empowering investor success. We provide a platform for our authors to report on investments fairly, accurately, and from the investor’s point of view.

  • ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating indiv idual securities.
  • Companies to develop and commercialize innovative products in the United States.
  • Open to Public Investing is a wholly-owned subsidiary of Public Holdings, Inc. (“Public Holdings”).
  • No offer to buy securities can be accepted, and no part of the purchase price can be received, until an offering statement filed with the SEC has been qualified by the SEC.

Insiders that own company stock include Charles Theuer, Ikarian Capital, Llc, Mark C Wiggins, Opaleye Management Inc, Saundra L Pelletier and Scott B Brown. The company is scheduled to release its next quarterly earnings announcement on Wednesday, May 10th 2023. Sign-up to receive the latest news and ratings for TRACON Pharmaceuticals and its competitors with MarketBeat’s FREE daily newsletter.

TRACON Pharmaceuticals Inc (TCON) Down 34.83% in Premarket Trading – InvestorsObserver

TRACON Pharmaceuticals Inc (TCON) Down 34.83% in Premarket Trading.

Posted: Tue, 25 Apr 2023 10:41:19 GMT [source]

Looking at the stock’s medium term indicators we note that it is averaging as a Hold, while an average of long term indicators are currently assigning the stock as 100% Sell. Brokerage services for US-listed, registered securities are offered to self-directed customers by Open to the Public Investing, Inc. (“Open to the Public Investing”), a registered broker-dealer and member of FINRA & SIPC. Additional information about your broker can be found by clicking here. Open to Public Investing is a wholly-owned subsidiary of Public Holdings, Inc. (“Public Holdings”). This is not an offer, solicitation of an offer, or advice to buy or sell securities or open a brokerage account in any jurisdiction where Open to the Public Investing is not registered.

Previous Post
Newer Post

Leave A Comment